Maxwell Tran, MD
Radiation Oncology · Gallipolis, OHNPI 1922595057
Payments from drug & device makers
Across 57 payments — averaging $21.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$169
- AstraZeneca$167
- Johnson & Johnson$124
- GSK$69
- Exelixis Inc.$62
- Sumitomo Pharma America, Inc.$59
- plus $590 from 21 others
What the payments were for
- Food & beverage$1,241100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 7 | $169 |
| AstraZeneca(2 entities) | 7 | $167 |
| Johnson & Johnson | 6 | $124 |
| GSK | 3 | $69 |
| Exelixis Inc. | 3 | $62 |
| Sumitomo Pharma America, Inc. | 3 | $59 |
| Merck | 2 | $52 |
| Daiichi Sankyo Inc. | 2 | $48 |
| AVEO Pharmaceuticals, Inc. | 2 | $40 |
| Genentech USA, Inc. | 2 | $38 |
| Pharmacosmos Therapeutics Inc. | 2 | $34 |
| Dendreon Pharmaceuticals LLC | 1 | $34 |
| Pfizer | 2 | $32 |
| Stemline Therapeutics Inc. | 2 | $32 |
| Sobi, Inc | 1 | $29 |
| Pharmaessentia USA Corporation | 1 | $28 |
| Incyte Corporation | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Servier Pharmaceuticals LLC | 1 | $24 |
| Beone Medicines USA, Inc. | 1 | $23 |
| Bristol Myers Squibb | 1 | $23 |
| Geron Corporation | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Karyopharm Therapeutics Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Iovance Biotherapeutics, Inc. | 1 | $15 |
| Taiho Oncology, Inc. | 1 | $14 |
How this compares
$1,241 in reported general payments places this provider in the 65th percentile of 255 radiation oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 18 | $284 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Gallipolis
- Shlomo KoyfmanCleveland$2.4M
- Arnab ChakravartiColumbus$1.4M
- Angela Yuanyuan JiaCleveland$1M
- Daniel SprattCleveland$834K
- Steven KurtzmanGarfield Heights$833K
- Jeremy BrownsteinColumbus$522K
- Sasha BeyerColumbus$504K
- John BrenemanCincinnati$503K
- Joshua PalmerColumbus$453K
- Kyle WangCincinnati$412K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.